caa a22 4500 445335432 CHVBK 20180317142753.0 cr unu---uuuuu 170323e20111001xx s 000 0 eng 10.1245/s10434-011-1715-2 doi (NATIONALLICENCE)springer-10.1245/s10434-011-1715-2 Mortality and Morbidity After Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Population-Based Study [Elektronische Daten] [Firas Abdollah, Maxine Sun, Rodolphe Thuret, Jan Schmitges, Shahrokh Shariat, Paul Perrotte, Francesco Montorsi, Pierre Karakiewicz] Purpose: To test whether the rates of in-hospital mortality, complications, and transfusions are higher in patients treated with cytoreductive nephrectomy (CNT) for metastatic renal cell carcinoma (mRCC) relative to patients treated with nephrectomy (NT) for non-mRCC. Methods: We assessed 17,688 patients treated with a NT between years 1999 and 2008, within the Florida Inpatient Database. Chi-square and Student t-tests were used to compare the statistical significance of differences in proportions and means, respectively. Univariable and multivariable logistic regression analyses tested the relationship between surgery type (CNT vs. NT) and three end points: in-hospital mortality, complications, and transfusions. Results: Overall, 6.0% of patients underwent CNT. The rates of in-hospital mortality, complications, and transfusions were 2.4, 26.5, and 24.3% in CNT patients versus 0.9, 18.9, and 11.1% in NT patients. At multivariable analyses, CNT patients demonstrated a 2.0-, 1.3-, and 2.4-fold higher risk of in-hospital mortality, complications, and transfusions (all P<0.001). Similarly, more advanced age, comorbidity, and the cumulative number of secondary surgical procedures were independent predictors of a higher risk of in-hospital mortality, complications, and transfusions (all P<0.001). Conclusions: The rate of in-hospital mortality, complications, and transfusions is higher in patients treated with CNT relative to NT. Older age, higher comorbidity, and the necessity of secondary surgical procedures further increases the risk of all aforementioned end points. Physicians should consider these observations during the planning of a CNT, and patients should be informed accordingly. Society of Surgical Oncology, 2011 Abdollah Firas Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada aut Sun Maxine Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada aut Thuret Rodolphe Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada aut Schmitges Jan Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada aut Shariat Shahrokh Department of Urology, Weill Medical College of Cornell University, New York, NY, USA aut Perrotte Paul Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada aut Montorsi Francesco Department of Urology, Vita Salute San Raffaele University, Milan, Italy aut Karakiewicz Pierre Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada aut Annals of Surgical Oncology Springer-Verlag 18/10(2011-10-01), 2988-2996 1068-9265 18:10<2988 2011 18 10434 https://doi.org/10.1245/s10434-011-1715-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-011-1715-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Abdollah Firas Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada aut NATIONALLICENCE 700 1- Sun Maxine Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada aut NATIONALLICENCE 700 1- Thuret Rodolphe Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada aut NATIONALLICENCE 700 1- Schmitges Jan Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada aut NATIONALLICENCE 700 1- Shariat Shahrokh Department of Urology, Weill Medical College of Cornell University, New York, NY, USA aut NATIONALLICENCE 700 1- Perrotte Paul Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada aut NATIONALLICENCE 700 1- Montorsi Francesco Department of Urology, Vita Salute San Raffaele University, Milan, Italy aut NATIONALLICENCE 700 1- Karakiewicz Pierre Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/10(2011-10-01), 2988-2996 1068-9265 18:10<2988 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer